Translational Dysregulation Driving Mesenchymal Cell Fibrogenic Transformation and Chronic Lung Allograft Dysfunction
翻译失调驱动间充质细胞纤维化转化和慢性同种异体肺移植功能障碍
基本信息
- 批准号:10864502
- 负责人:
- 金额:$ 57.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-12-08 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Airway FibrosisAllograftingAutocrine CommunicationAutomobile DrivingBronchiolitis ObliteransCause of DeathCell SeparationCellsChronicClinicalCollagenCytometryDataDefectDepositionDevelopmentEukaryotic Initiation FactorsEvaluationEventFRAP1 geneFailureFibrosisFunctional disorderFutureGeneticHistologicHumanImmuneImmunodeficient MouseImmunosuppressionIn VitroInflammatoryInterventionInvestigationKnock-outLesionLifeLipidsLungLung TransplantationLysophospholipaseMalignant NeoplasmsMesenchymalMessenger RNAMitogen-Activated Protein KinasesModelingMolecularMusMutant Strains MiceOncogenicOralOrgan TransplantationOutcomePathogenesisPathway interactionsPatientsPhenotypePhosphorylationPhosphotransferasesPlayProceduresProtein KinaseProtein-Serine-Threonine KinasesProteinsProteomicsPublishingResistanceRoleSchemeSerineSignal PathwaySignal TransductionSolidSyndromeTestingTherapeuticTherapeutic TrialsTranscriptional ActivationTransgenic MiceTranslational ActivationTranslational RegulationTranslationsTransplant RecipientsTransplantationWorkautocrinebeta catenincytokineefficacy evaluationfibrogenesisgraft failureimprovedin vitro activityin vivoinflammatory milieuinhibitorkinase inhibitorlung allograftmetaplastic cell transformationnew therapeutic targetnovelnovel therapeutic interventionpharmacologicpost-transplantpreclinical studypreventprogramsprotein expressionpulmonary functionribosome profilingsmall moleculetransplant modeltumorigenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
Chronic lung allograft dysfunction (CLAD) marked by progressive graft failure develops in 50% of lung transplant
recipients by 5 years and is the major cause of poor-long term outcomes after this life-saving procedure.
Predominant clinical presentation is development of persistent obstructive ventilatory defect termed bronchiolitis
obliterans syndrome (BOS) resulting from fibrotic obliteration of the small airways or bronchiolitis obliterans (BO).
Graft-resident mesenchymal cells (MCs) play a key role in pathogenesis of BO and our recent studies
demonstrate that autonomous activation of MCs marked by increased matrix deposition and stable activation of
pro-fibrotic pathways is a key driver of the allograft fibrosis and dysfunction. Various signaling pathways were
shown to converge at the level of eukaryotic translation initiation factor 4E (eIF4E) to regulate key fibrotic
functions like collagen I expression in BOS MCs. In this application we aim to investigate the role of MAP kinase–
interacting serine/threonine kinase (MNK) induced direct phosphorylation of eIF4E at serine 209 in maintaining
fibrogenic transformation of BOS MCs and determine the contribution of MNK/eIF4E pathway to pathogenesis
of BO post-transplantation. MNK kinase induced phosphorylation of eIF4E at serine 209 has been demonstrated
to be critical in promoting its oncogenic potential but has not been investigated in the context of fibrosis. Our
preliminary data demonstrates a constitutively higher eIF4E phosphorylation at Serine209 in MCs from patients
with BOS. eIF4E phospho-S209 was found to be critical in regulating key fibrogenic protein autotaxin and
sustaining the fibrotic functions of BOS MCs. MNK signaling was upregulated in BOS cells and genetic or
pharmacologic targeting of MNK activity inhibited eIF4E phospho-S209 and fibrotic functions of BOS MCs in
vitro. In vivo treatment with MNK inhibitor eFT-508 was found to decrease allograft fibrosis in orthotopic murine
lung transplant model. In Aim 1 we will utilize MCs derived from patients ± BOS to dissect the molecular
mechanisms via which eIF4E Ser209 phosphorylation contributes to fibrogenic transformation of human lung
MCs. Aim 2 will investigate the role of MNK/eIF4E signaling in development of BO in a murine orthotopic lung
transplant model of BO by utilizing MNK1/2 Knockout and eIF4ES209A/A mutant mice to target MNK/eIF4E S209
in donor lungs. Preclinical studies of a novel orally available MNK1/2 inhibitor eFT508 in murine orthotopic whole
lung transplant BO model with assessment of fibrotic and immune/inflammatory endpoints proposed in Aim 3
will lay the background for future human therapeutic trials. Together these studies will shed novel light on the
role of MNK/eIF4E Ser209 phosphorylation in fibrotic activation of MCs and test its potential as an attractive
target for halting fibrogenic progression and development of CLAD.
项目总结/摘要
慢性肺移植物功能障碍(CLAD)的特点是进行性移植失败的发展,在50%的肺移植
接受者5年,是这种挽救生命的手术后长期结果不佳的主要原因。
主要的临床表现是发展为持续性阻塞性毛细血管缺陷,称为细支气管炎
闭塞性综合征(BOS)是由小气道的纤维化闭塞或闭塞性细支气管炎(BO)引起的。
移植物驻留间充质细胞(mesenchymal cells,MCs)在BO的发病机制中起着关键作用,
表明MCs的自主激活以基质沉积增加和MCs的稳定激活为标志,
促纤维化途径是同种异体移植物纤维化和功能障碍的关键驱动因素。各种信号传导途径,
显示在真核翻译起始因子4 E(eIF 4 E)水平上会聚,以调节关键的纤维化
在BOS MC中的功能类似于胶原I表达。在本申请中,我们的目标是研究MAP激酶的作用-
相互作用的丝氨酸/苏氨酸激酶(MNK)诱导eIF 4 E在丝氨酸209处的直接磷酸化,
BOS MCs的纤维化转化,并确定MNK/eIF 4 E途径对发病机制的贡献
移植后的BO已经证明MNK激酶诱导eIF 4 E在丝氨酸209处的磷酸化
在促进其致癌潜力方面至关重要,但尚未在纤维化的背景下进行研究。我们
初步数据表明,在来自患者的MC中,eIF 4 E在丝氨酸209处的磷酸化组成性更高,
关于BOS发现eIF 4 E磷酸-S209在调节关键的纤维化蛋白autotaxin中至关重要,
维持BOS MC的纤维化功能。MNK信号在BOS细胞中上调,遗传或
MNK活性的药理学靶向抑制EIF 4 E磷酸化S209和BOS MC的纤维化功能,
体外发现用MNK抑制剂eFT-508的体内治疗减少原位小鼠中的同种异体移植物纤维化。
肺移植模型在目标1中,我们将利用来源于患者± BOS的MC来解剖分子结构。
eIF 4 E Ser 209磷酸化促进人肺纤维化转化的机制
MC目的2将在小鼠原位肺中研究MNK/eIF 4 E信号传导在BO发生中的作用
利用MNK 1/2 Knockout和eIF 4 ES 209 A/A突变小鼠靶向MNK/eIF 4 ES 209建立BO移植模型
捐赠者的肺里新型口服MNK 1/2抑制剂eFT 508在小鼠原位全细胞中的临床前研究
肺移植BO模型,评估目的3中提出的纤维化和免疫/炎症终点
将为未来的人体治疗试验奠定基础。这些研究将共同揭示新的光
MNK/eIF 4 E Ser 209磷酸化在MC纤维化活化中的作用,并测试其作为有吸引力的
目的是阻止纤维化进展和CLAD的发展。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lysophosphatidic acid induces migration of human lung-resident mesenchymal stem cells through the β-catenin pathway.
- DOI:10.1002/stem.1171
- 发表时间:2012-09
- 期刊:
- 影响因子:5.2
- 作者:Badri, Linda;Lama, Vibha N.
- 通讯作者:Lama, Vibha N.
Quantitative CT Correlates with Local Inflammation in Lung of Patients with Subtypes of Chronic Lung Allograft Dysfunction.
- DOI:10.3390/cells11040699
- 发表时间:2022-02-16
- 期刊:
- 影响因子:6
- 作者:Ram S;Verleden SE;Bell AJ;Hoff BA;Labaki WW;Murray S;Vanaudenaerde BM;Vos R;Verleden GM;Kazerooni EA;Galbán S;Hatt CR;Han MK;Lama VN;Galbán CJ
- 通讯作者:Galbán CJ
Ecto-5'-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation.
- DOI:10.4049/jimmunol.0901847
- 发表时间:2010-07-15
- 期刊:
- 影响因子:0
- 作者:Ohtsuka T;Changelian PS;Bouïs D;Noon K;Harada H;Lama VN;Pinsky DJ
- 通讯作者:Pinsky DJ
Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis.
- DOI:10.1038/s41598-020-77601-1
- 发表时间:2020-12-04
- 期刊:
- 影响因子:4.6
- 作者:Cao P;Walker NM;Braeuer RR;Mazzoni-Putman S;Aoki Y;Misumi K;Wheeler DS;Vittal R;Lama VN
- 通讯作者:Lama VN
Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allografts.
- DOI:10.1016/j.ajpath.2011.01.058
- 发表时间:2011-06
- 期刊:
- 影响因子:0
- 作者:N. Walker;Linda N Badri;S. Wettlaufer;A. Flint;U. Sajjan;P. Krebsbach;V. Keshamouni;M. Peters-Golden;V. Lama
- 通讯作者:N. Walker;Linda N Badri;S. Wettlaufer;A. Flint;U. Sajjan;P. Krebsbach;V. Keshamouni;M. Peters-Golden;V. Lama
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vibha N Lama其他文献
Vibha N Lama的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vibha N Lama', 18)}}的其他基金
Pathogenesis of Restrictive Allograft Syndrome Post-Lung Transplantation
肺移植后限制性同种异体移植综合征的发病机制
- 批准号:
10383970 - 财政年份:2021
- 资助金额:
$ 57.46万 - 项目类别:
Pathogenesis of Restrictive Allograft Syndrome Post-Lung Transplantation
肺移植后限制性同种异体移植综合征的发病机制
- 批准号:
10532251 - 财政年份:2021
- 资助金额:
$ 57.46万 - 项目类别:
Autotaxin Lysophophatidic acid pathway in bronchiolitis obliterans post-lung tran
肺移植后闭塞性细支气管炎中自分泌运动因子溶血磷脂酸途径
- 批准号:
8694759 - 财政年份:2014
- 资助金额:
$ 57.46万 - 项目类别:
Role of Resident Mesenchymal Stem Cells in Lung Allograft Rejection
驻留间充质干细胞在肺同种异体移植排斥反应中的作用
- 批准号:
8974429 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Translational Dysregulation Driving Mesenchymal Cell Fibrogenic Transformation and Chronic Lung Allograft Dysfunction
翻译失调驱动间充质细胞纤维化转化和慢性同种异体肺移植功能障碍
- 批准号:
10593165 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Role of resident mesenchymal stem cells in lung allograft rejection
常驻间充质干细胞在肺同种异体移植排斥反应中的作用
- 批准号:
7900517 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Role of resident mesenchymal stem cells in lung allograft rejection
常驻间充质干细胞在肺同种异体移植排斥反应中的作用
- 批准号:
8268427 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Role of resident mesenchymal stem cells in lung allograft rejection
常驻间充质干细胞在肺同种异体移植排斥反应中的作用
- 批准号:
8499392 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Role of resident mesenchymal stem cells in lung allograft rejection
常驻间充质干细胞在肺同种异体移植排斥反应中的作用
- 批准号:
8078103 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Translational Dysregulation Driving Mesenchymal Cell Fibrogenic Transformation and Chronic Lung Allograft Dysfunction
翻译失调驱动间充质细胞纤维化转化和慢性同种异体肺移植功能障碍
- 批准号:
10374872 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
相似海外基金
Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
- 批准号:
26462277 - 财政年份:2014
- 资助金额:
$ 57.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
- 批准号:
8344380 - 财政年份:2012
- 资助金额:
$ 57.46万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7878675 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
- 批准号:
7677758 - 财政年份:2009
- 资助金额:
$ 57.46万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7466112 - 财政年份:2008
- 资助金额:
$ 57.46万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8010394 - 财政年份:2008
- 资助金额:
$ 57.46万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
8208131 - 财政年份:2008
- 资助金额:
$ 57.46万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7575273 - 财政年份:2008
- 资助金额:
$ 57.46万 - 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
- 批准号:
7765518 - 财政年份:2008
- 资助金额:
$ 57.46万 - 项目类别: